Avilar Therapeutics Receives U.S. Patent for Novel Extracellular Protein Degraders
Avilar Therapeutics to Present New Data for ATAC Extracellular Protein Degraders at Targeted Protein Degradation Summit
Avilar Therapeutics to Present at Upcoming Industry Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that Adam Muzikant, Ph.D., the company’s Chief Business Officer, will present at the upcoming Wells Fargo Healthcare Conference in Boston at 4:30 pm ET on Wednesday, September 6, 2023.
Avilar Therapeutics Increases Financing to $75 Million to Advance Pipeline of Novel Extracellular Protein Degraders
The venture arms of Sanofi and Astellas have grown their investment in Avilar Therapeutics to help steer the biotech through a niche of the growing protein degradation field.
WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today presented new preclinical proof-of-concept data demonstrating the degradation of extracellular proteins using its asialoglycoprotein receptor (ASGPR) targeting chimera (ATAC) platform at the Keystone Symposium on Targeted Protein Degradation being held in Vancouver, British Columbia. The company presented in vivo proof-of-concept data in non-human primates showing robust and dose-dependent degradation of a circulating extracellular protein by a monovalent ATAC degrader.
WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced it will present preclinical data demonstrating the degradation of extracellular proteins using its asialoglycoprotein receptor (ASGPR) targeting chimeras (ATAC) platform at the Keystone Symposium on Targeted Protein Degradation being held in Vancouver, British Columbia, November 6-8, 2022.